343 related articles for article (PubMed ID: 24073949)
21. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
22. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
23. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay.
Kristen AV; Giannitsis E; Lehrke S; Hegenbart U; Konstandin M; Lindenmaier D; Merkle C; Hardt S; Schnabel PA; Röcken C; Schonland SO; Ho AD; Dengler TJ; Katus HA
Blood; 2010 Oct; 116(14):2455-61. PubMed ID: 20581312
[TBL] [Abstract][Full Text] [Related]
24. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems.
Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F
Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869
[TBL] [Abstract][Full Text] [Related]
26. Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis.
Cappelli F; Baldasseroni S; Bergesio F; Padeletti L; Attanà P; Pignone AM; Grifoni E; Ciuti G; Fabbri A; Tarantini F; Marchionni N; Gensini GF; Perfetto F
Amyloid; 2014 Jun; 21(2):97-102. PubMed ID: 24517408
[TBL] [Abstract][Full Text] [Related]
27. Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.
Ingebrigtsen A; Saeed S; Larsen TH; Reikvam H
Scand J Clin Lab Invest; 2024 May; 84(3):193-201. PubMed ID: 38709651
[TBL] [Abstract][Full Text] [Related]
28. Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.
Kumar SK; Gertz MA; Dispenzieri A
J Clin Oncol; 2019 Jan; 37(2):171-173. PubMed ID: 30433848
[No Abstract] [Full Text] [Related]
29. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
[TBL] [Abstract][Full Text] [Related]
30. Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.
Bhutani D; Pan S; Latif F; Goldsmith RL; Saith SE; Mapara MY; Chakraborty R; Lentzsch S; Maurer MS
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):545-548. PubMed ID: 34024744
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of Left Ventricular
Clerc OF; Datar Y; Cuddy SA; Bianchi G; Taylor A; Benz DC; Robertson M; Kijewski MF; Jerosch-Herold M; Kwong RY; Ruberg FL; Liao R; Di Carli MF; Falk RH; Dorbala S
medRxiv; 2023 Sep; ():. PubMed ID: 37745589
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic score of cardiac involvement in AL amyloidosis.
Nicol M; Baudet M; Brun S; Harel S; Royer B; Vignon M; Lairez O; Lavergne D; Jaccard A; Attias D; Macron L; Gayat E; Cohen-Solal A; Arnulf B; Logeart D
Eur Heart J Cardiovasc Imaging; 2020 May; 21(5):542-548. PubMed ID: 31292624
[TBL] [Abstract][Full Text] [Related]
33. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; McConnell JP; Litzow MR; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata LF; Elliott MA; Hogan WJ; Rajkumar SV; Fonseca R; Greipp PR; Witzig TE; Lust JA; Zeldenrust SR; Snow DS; Hayman SR; McGregor CG; Jaffe AS
Blood; 2004 Sep; 104(6):1881-7. PubMed ID: 15044258
[TBL] [Abstract][Full Text] [Related]
34. The predictive value of NT-proBNP and hs-TnT for risk of death in cardiac surgical patients.
Brynildsen J; Petäjä L; Pettilä V; Nygård S; Vaara ST; Linko R; Okkonen M; Hagve TA; Soininen L; Suojaranta-Ylinen R; Lyngbakken MN; Omland T; Røsjø H
Clin Biochem; 2018 Mar; 53():65-71. PubMed ID: 29371002
[TBL] [Abstract][Full Text] [Related]
35. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.
Björklund E; Jernberg T; Johanson P; Venge P; Dellborg M; Wallentin L; Lindahl B;
Heart; 2006 Jun; 92(6):735-40. PubMed ID: 16251228
[TBL] [Abstract][Full Text] [Related]
36. Natural history and therapy of AL cardiac amyloidosis.
Grogan M; Dispenzieri A
Heart Fail Rev; 2015 Mar; 20(2):155-62. PubMed ID: 25447844
[TBL] [Abstract][Full Text] [Related]
37. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
38. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
[TBL] [Abstract][Full Text] [Related]
39. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
40. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis.
Damy T; Deux JF; Moutereau S; Guendouz S; Mohty D; Rappeneau S; Guellich A; Hittinger L; Loric S; Lefaucheur JP; Plante-Bordeneuve V
Amyloid; 2013 Dec; 20(4):212-20. PubMed ID: 23964755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
